CCM
TVRD

Cadence Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Cadence Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,071
Closed -$656K – 597
2014
Q2 		$656K Buy
+1,071
New +$577K 0.03% 461

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cadence Capital Management's TVRD Position: Q3 2014 in Review

Cadence Capital Management sold out of Tvardi Therapeutics (TVRD) in Q3 2014, closing a stake of 1,071 shares — an estimated $656K sold.

Cadence Capital Management first reported a position in TVRD in Q2 2014 and held it in 1 quarter. The position peaked at $656K in Q2 2014. 56 funds tracked by Wall St. Rank hold TVRD as of Q3 2014.

  • Cadence Capital Management reported no remaining Tvardi Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Cadence Capital Management sold 1,071 Tvardi Therapeutics shares in Q3 2014, an estimated $656K.
  • Cadence Capital Management first reported a position in Tvardi Therapeutics in Q2 2014 and held it in 1 quarter.
  • Cadence Capital Management's Tvardi Therapeutics position peaked at $656K in Q2 2014.
  • 56 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2014.

Based on Cadence Capital Management's 13F filing for Q3 2014, filed 3 Nov 2014.